InvestorsHub Logo
icon url

flipper44

06/04/19 10:39 PM

#231448 RE: GoodGuyBill #231446

Yes I see a problem with it, but no I don't think NWBO can be blamed for toning down the theater presentation, particularly when they are about to dialogue with regulators on the SAP, and hopefully soon, a BLA. The other problem as I see it is debt financing conflict, but I've never seen that challenged, and I think LP is, for better or worse, showing other small pharma CEOs how to thrive (but not necessarily their investors) -- if you have a good product. We are in a fragile window of time. Down the road, nobody would question NWBO playing presentations conservatively at this point. The depth and volume description of the SAP surprised me, and it also likely protects NWBO from backseat drivers down the road, as does their obvious (we learned in hindsight) desire for sufficient maturity. Of course this is all subject to further questioning if they propose yet another delay. Which I pray they do not. Good luck to patients.
icon url

MI Dendream

06/04/19 11:51 PM

#231458 RE: GoodGuyBill #231446

What does reason number 2 even mean? Is Flip suggesting LP is keeping a lid on the price because they don’t want to get too much money from a BP company?

OMG - I am going to lose it? What was the name of that platinum Talking Heads album?

Uhmmm, hmmmmm, uhmmm... I think Roche and Novartis have something like $200B in cash and investments each. Roche took out the biggest American Biotech with ease. Are we looking at the same industry here? I am no longer sure.
icon url

drugrunner

06/04/19 11:51 PM

#231459 RE: GoodGuyBill #231446

Number 2- quite possibly the dumbest statement - comment- belief on this topic

Not wanting the stock price to rise too high as not to offend BP

F-Ing please

Raise the share price enough to raise capital on your and F BIG PHARMA

LET THEM BUYOUT NWBO at a huge premium
icon url

Goodtime13

06/05/19 12:12 AM

#231463 RE: GoodGuyBill #231446

This must be a joke...right? You both realize that their market cap is a rounding error for most biotechs.

Let’s see...the share price is down 95% over the last 4-years, they’ve diluted and diluted and diluted....and you think they want to keep the share price low for a buyout?

What in God’s name am I reading and why do I bother reading this stuff anymore?

Seriously, you both must be joking! You cannot be serious!